GlassScriptPhysician profile
Mariam Alkawally
NPI 1710597240
$417.04
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
See the full distribution for Corneal and Contact Management
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $95.20 · 2021: $302 · 2022: $19.38.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $214.17 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $49.27 | 2021 | |
| Sun Pharmaceutical Industries INC. | $41.06 | 2020-2021 | |
| Johnson & Johnson Surgical Vision, INC. | $40.46 | 2021 | |
| Biotissue Holdings INC. | $36.56 | 2021-2022 | |
| Coopervision INC. | $21.72 | 2020 | |
| Allergan, INC. | $13.80 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mariam Alkawally listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.